Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has received marketing authorisation from European Commission (EC) for its Revolade (eltrombopag), used in the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Subscribe to our email newsletter
According to GSK, Eltrombopag is indicated for adult chronic ITP splenectomised patients who are refractory (have not responded) to other treatments, such as corticosteroids and immunoglobulins. Eltrombopag may also be considered as second-line treatment for adult non-splenectomised patients where surgery is contraindicated.
Eltrombopag was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals, and is developed by GSK.